JULÄINE™ - Neck Skin Laxity Clinical Investigation
A Prospective, Multi-Centre, Single-Arm, Open-Label Pivotal Clinical Investigation to Evaluate the Safety and Clinical Performance of JULÄINE™ in Adults With Neck Skin Laxity
This study will assess the safety of JULÄINE™, an injectable filler containing poly-L-lactic acid (PLLA), and whether it can improve loose skin on the neck.
The main question is whether more than 60% of treated participants show an improvement of at least one level on a neck skin laxity scale, 26 weeks after their final treatment. Improvement will be measured by comparing neck skin looseness before and after treatment.
The study plans to enroll adults aged 18 years or older with mild to moderately severe loose neck skin at three sites. All participants will receive the filler during three treatment sessions, approximately four weeks apart.
Participation will last approximately 14 months, including screening, treatment, and follow-up until 52 weeks after the final treatment. Investigators will assess changes using standardised photographs, measurements of skin elasticity, and questionnaires about participants' views of their neck appearance. The study will also monitor adverse events through the final follow-up visit.
調査の概要
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Karina Caramico
- 電話番号:(+46) 76 336 39 48
- メール:k.caramico@nordbergmedical.com
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Adults aged 18 years or older with mild to moderate-to-severe neck skin laxity (Grade 2-4 on Neck Laxity Scale).
- Willing to avoid aesthetic procedures involving the neck and lower face and changes to treatments affecting skin quality during the study.
- If of childbearing potential, a negative pregnancy test and agreement to use highly effective contraception throughout treatment and for eight weeks afterward.
- Able to provide written informed consent and comply with study visits, assessments, and post-treatment instructions.
Exclusion Criteria:
- Pregnancy, breastfeeding, or planned pregnancy or reproductive donation/retrieval procedures during the study or within eight weeks after the final visit.
- Previous neck surgery or major maxillofacial/cervical surgery; neck injections within 12 months; neck resurfacing or other aesthetic procedures within six months; or planned procedures during the study.
- Significant neck skin disease, infection, scarring, pigmentation abnormalities, or other conditions interfering with treatment or assessment.
- Prominent neck muscle bands, excessive facial or neck fat, or anatomy unsuitable for injectable treatment, as assessed by the investigator.
- Significant thyroid enlargement, uncontrolled thyroid disease, or other unstable endocrine disease.
- Allergy to device components, coagulation disorders, or anticoagulant/antiplatelet treatment, subject to protocol-defined exceptions.
- Recent immune-modifying treatment, chemotherapy, or systemic corticosteroids above 10 mg prednisone-equivalent daily; relevant corticosteroid/retinoid use; or treatments affecting collagen production.
- Hormone replacement therapy or thyroid medication that does not meet protocol-defined stability requirements.
- Immune deficiency, autoimmune disease, impaired wound healing, or significant malignant, dermatological, or systemic disease.
- Significant recent or expected weight changes, recent bariatric surgery, ongoing postoperative weight loss, or active weight-loss treatment, subject to protocol-defined exceptions.
- Any condition preventing valid informed consent or compliance with study requirements.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:JULÄINE™
|
JULÄINE™, a poly-L-lactic acid (PLLA)-based injectable filler, administered beneath the skin on both sides of the neck during three treatment sessions, approximately four weeks apart. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants With Improved Neck Skin Laxity
時間枠:Baseline and 26 weeks after the final treatment session
|
Percentage of participants showing an improvement of at least one grade from baseline on Neck Laxity Scale. The scale ranges from Grade 1 to Grade 5. A decrease in grade indicates improvement. |
Baseline and 26 weeks after the final treatment session
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Percentage of Participants With Improved Neck Skin Laxity at 12 and 52 Weeks
時間枠:Baseline and 12 and 52 weeks after the final treatment session
|
Percentage of participants showing an improvement of at least one grade from baseline on Neck Laxity Scale. The scale ranges from Grade 1 to Grade 5. A decrease in grade indicates improvement. |
Baseline and 12 and 52 weeks after the final treatment session
|
|
Percentage of Participants With Improved Neck Skin Elasticity
時間枠:Baseline and 26 weeks after the final treatment session
|
Percentage of participants showing an increase of at least 10% from baseline in the Cutometer R2 parameter, a measure of overall skin elasticity. Higher R2 values indicate greater elasticity. |
Baseline and 26 weeks after the final treatment session
|
|
Investigator-Rated Change in Neck Appearance
時間枠:12, 26, and 52 weeks after the final treatment session
|
Distribution of investigator ratings on the seven-point Global Aesthetic Improvement Scale, ranging from "very much improved" to "very much worse," based on comparisons of standardised post-treatment and baseline photographs. |
12, 26, and 52 weeks after the final treatment session
|
|
Change From Baseline in FACE-Q Appraisal of the Neck Score
時間枠:Baseline and 12, 26, and 52 weeks after the final treatment session.
|
Change from baseline in participants' assessment of their neck appearance using the FACE-Q Appraisal of the Neck questionnaire. Raw scores are converted to a score ranging from 0 to 100 using the instrument's scoring algorithm. |
Baseline and 12, 26, and 52 weeks after the final treatment session.
|
|
Change From Baseline in Neck Skin Firmness and Elasticity Measured by Cutometer
時間枠:Baseline and 12, 26, and 52 weeks after the final treatment session.
|
Change from baseline in four Cutometer parameters: R0 (skin firmness), R2 (gross elasticity), R5 (net elasticity), and R7 (biological elasticity). Lower R0 values indicate firmer skin, while higher R2, R5, and R7 values indicate greater elasticity. |
Baseline and 12, 26, and 52 weeks after the final treatment session.
|
|
Incidence of Adverse Events and Device Deficiencies
時間枠:From the first treatment through 52 weeks after the final treatment session
|
Number and percentage of participants experiencing adverse events, including device-related events, serious events, and unanticipated serious device-related events. Events will be characterised by type, severity, seriousness, and relationship to the device or injection procedure. Device deficiencies will be summarised separately. |
From the first treatment through 52 weeks after the final treatment session
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- NB 15-TF-EU-100-38F
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。